Having trouble accessing articles? Reset your cache.

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

Catalent buys Italian facility from BMS
Catalent Inc. (NYSE:CTLT) will buy an Italian manufacturing facility from Bristol-Myers Squibb Co. (NYSE:BMY) for an undisclosed amount. Catalent will manufacture oral solid, biologics and sterile products at the site, and will also continue to manufacture BMS's products. The

Read the full 443 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE